



Roche's Announcement Regarding divarasib (Announcement of Phase III Krascendo1 Study Results)

TOKYO, July 2, 2026 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a media release on July 2, regarding the results of the global Phase III clinical trial (Krascendo1) evaluating the KRAS G12C inhibitor divarasib in previously treated KRAS G12C-positive non-small cell lung cancer.

The detailed data will be presented at an upcoming medical meeting.

Please refer to the link below for details of the media release:

Roche's divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

<https://www.roche.com/media/releases/med-cor-2026-07-02>

###